--(BUSINESS WIRE)--Reven Holdings, Inc., a Delaware corporation, through its Golden, Colorado, based operating company Reven, LLC, is a biopharmaceutical company. Reven’s vision is to make a difference in the world by making its products accessible to everyone suffering the effects of vascular and metabolic related diseases. Reven is committed to being the premier, research-intensive biopharmaceutical company that advances the health and well-being of people around the world. Its primary product, Rejuveinix (RJX), targets patients suffering from COVID-19, sepsis, vascular and metabolic related diseases as well as specific patient populations suffering PAD and other cardiovascular related medical conditions.
Company: |
Reven, LLC |
|
|
|
|
Headquarters Address: |
600 Corporate Circle |
|
|
Suite D |
|
|
Golden, CO 80401 |
|
|
|
|
Main Telephone: |
(425) 305-9547 |
|
|
|
|
Website: |
||
|
|
|
Type of Organization: |
Private |
|
|
|
|
Industry: |
Biotechnology |
|
|
|
|
Key Executives: |
CEO: Peter Lange |
|
|
COO: Brian Denomme |
|
|
CFO: Jeff Halverson |
|
|
|
|
Investor Relations |
|
|
Contact: |
Jennifer Van Tuinen |
|
Phone: |
(720) 618-0658 |
|
Email: |
||
|
|
|
Public Relations |
|
|
Contact: |
Vincent Vanderbent |
|
Phone: |
(425) 305-9547 |
|
Email: |
